Aligos Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Aligos Therapeutics, Inc. (ALGS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.29 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2022-11-02
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-09-30 was $3.29M, a 224.31% increase year-over-year.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-06-30 was $3.21M, a 881.35% increase year-over-year.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-03-31 was $2.76M, a 732.63% increase year-over-year.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2020-12-31 was $1.30M, a 779.05% increase year-over-year.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $2.98M, a 295.61% increase from fiscal 2019.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2019 was $752.00K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2021-09-30 | $3.29M 10-Q · filed 2022-11-02 | $6.50M derived: sum of 2 quarters · filed 2022-11-02 | $9.26M 10-Q · filed 2022-11-02 | $10.56M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $3.21M 10-Q · filed 2022-08-04 | $5.96M 10-Q · filed 2022-08-04 | $7.27M derived: sum of 3 quarters · filed 2022-08-04 | $8.28M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $2.76M 10-Q · filed 2022-05-04 | $4.06M derived: sum of 2 quarters · filed 2022-05-04 | $5.07M derived: sum of 3 quarters · filed 2022-05-04 | $5.40M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $2.32M derived: sum of 2 quarters · filed 2022-03-10 | $2.64M derived: sum of 3 quarters · filed 2022-03-10 | $2.98M 10-K · filed 2022-03-10 |
| 2020-09-30 | $1.02M 10-Q · filed 2021-11-04 | $1.34M derived: sum of 2 quarters · filed 2021-11-04 | $1.67M 10-Q · filed 2021-11-04 | $1.82M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $327.00K 10-Q · filed 2021-08-05 | $658.00K 10-Q · filed 2021-08-05 | $806.00K derived: sum of 3 quarters · filed 2021-08-05 | $957.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $331.00K 10-Q · filed 2021-05-10 | $479.00K derived: sum of 2 quarters · filed 2021-05-10 | $630.00K derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | $148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $299.00K derived: sum of 2 quarters · filed 2021-03-23 | $752.00K 10-K · filed 2021-03-23 | |
| 2019-09-30 | $151.00K 10-Q · filed 2020-11-25 | $604.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |